{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:19:41Z","timestamp":1753881581270,"version":"3.41.2"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2024,11,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>Hematological cancers, including Leukemias and Lymphomas, and their associated chemotherapy and disease-specific factors, are linked to impaired granulocyte function and numbers, increasing the risk of opportunistic infections, often presenting as fever. Human cytomegalovirus (HCMV) is one of the significant opportunistic infections in these patients, but limited data exists on its seroprevalence and active infection burden among febrile hematological cancer patients in Uganda. We conducted a cross-sectional study from June to August 2017 at the Uganda Cancer Institute (UCI). Blood samples from 161 febrile hematological cancer patients were collected. HCMV exposure was assessed using indirect enzyme-linked immunosorbent assay for IgG and IgM antibodies, and active infection was confirmed with PCR testing and gel electrophoresis. IgG positivity indicated previous exposure, while positive IgM or PCR results indicated active infection. Overall, HCMV seroprevalence based on IgG and\/or IgM positivity was 106\/161 (66%). IgG alone, IgM alone, and combined IgG\/IgM positivity prevalence rates were 57\/161 (35.4%), 22\/161 (13.6%), and 27\/161 (16.7%), respectively. HCMV DNA PCR was positive in 5 of the 161 (3%) samples. Among PCR-positive patients, one (20%) was positive for IgG alone, two (40%) for IgM alone, and two (40%) for both IgG and IgM. Active infection based on positive IgM and HCMV DNA PCR was found in 23 of the 161 (14.3%) patients. Two-thirds of febrile patients with hematological malignancies in Uganda had been exposed to HCMV infection, with 14.3% showing active infection. Routine testing for active HCMV infection among febrile hematological cancer patients at the UCI is essential for timely and appropriate antiviral treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>IMPORTANCE<\/jats:title>\n            <jats:p>In this paper, we demonstrated that over two-thirds of feverish patients with blood cancers such as leukemia at the Uganda Cancer Institute are already exposed to a type of virus infection called the human cytomegalovirus (HCMV), and 14% of the patients have active disease due to this virus. This was confirmed through finding blood samples testing positive for a type of protective antibody called IgM and also upon virus DNA detection in the blood of those patients. Routine testing for this virus is not usually done in the study settings. Our findings reveal and emphasize the importance of routinely testing blood samples for active infection with this virus among the feverish patients with blood cancers in the study settings, and prompt initiation of antiviral treatment of the actively infected patients<\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/spectrum.00481-24","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T13:23:09Z","timestamp":1726752189000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Human cytomegalovirus infection among febrile hematological cancer patients at the Uganda Cancer Institute"],"prefix":"10.1128","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8021-1398","authenticated-orcid":true,"given":"Ocung","family":"Guido","sequence":"first","affiliation":[{"name":"Department of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda"},{"name":"National Tuberculosis Reference Laboratory\/WHO Supranational Reference Laboratory, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Lubwama","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Makerere University College of Health Sciences, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prossy","family":"Kiconco","sequence":"additional","affiliation":[{"name":"MBN Clinical Laboratories, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"Okeng","sequence":"additional","affiliation":[{"name":"MBN Clinical Laboratories, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Najjingo","sequence":"additional","affiliation":[{"name":"Makerere University Lung Institute, College of Health Sciences, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Aboce","sequence":"additional","affiliation":[{"name":"MBN Clinical Laboratories, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rembo","family":"Phiona","sequence":"additional","affiliation":[{"name":"Uganda Cancer Institute, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanifah","family":"Nabbanja","sequence":"additional","affiliation":[{"name":"Uganda Cancer Institute, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariam","family":"Ndagire","sequence":"additional","affiliation":[{"name":"Uganda Cancer Institute, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamala","family":"Eva","sequence":"additional","affiliation":[{"name":"Uganda Cancer Institute, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wekiya","family":"Enock","sequence":"additional","affiliation":[{"name":"National Tuberculosis Reference Laboratory\/WHO Supranational Reference Laboratory, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackson","family":"Orem","sequence":"additional","affiliation":[{"name":"Uganda Cancer Institute, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moses L.","family":"Joloba","sequence":"additional","affiliation":[{"name":"Department of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda"},{"name":"National Tuberculosis Reference Laboratory\/WHO Supranational Reference Laboratory, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8898-0992","authenticated-orcid":true,"given":"Freddie","family":"Bwanga","sequence":"additional","affiliation":[{"name":"Department of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda"},{"name":"MBN Clinical Laboratories, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-387092"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210"},{"key":"e_1_3_4_4_2","unstructured":"El-Gewely R. 2018. Studying of non-malignant tumors and the added clarifications"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21262"},{"key":"e_1_3_4_6_2","unstructured":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries - Bray - 2018 - CA: A Cancer Journal for Clinicians - Wiley Online Library. Wiley Online Library [Internet]. Available from: https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full\/10.3322\/caac.21492. Retrieved 20 Nov 2022"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018GS111079"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/986938"},{"key":"e_1_3_4_9_2","unstructured":"Kjellander C. 2016. Bloodstream infections in patients with hematological malignancies [Internet]. Inst f\u00f6r med Solna \/ Dept of Med Solna. Available from: http:\/\/openarchive.ki.se\/xmlui\/handle\/10616\/45110"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00198-8"},{"key":"e_1_3_4_11_2","unstructured":"Ferlay J Shin HR Bray F Forman D Mathers C ParkinDM GLOBOCAN 2008. 2009. Cancer incidence and mortality worldwide: IARC CancerBase No. 10. Lyon France: International Agency for Research on Cancer. 2008. Available from: https:\/\/hero.epa.gov\/hero\/index.cfm\/reference\/details\/reference_id\/758659. Retrieved 20 Nov 2022."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22032"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-019-4520-9"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.13-2-185"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.2921"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.368"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/leusup.2012.15"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061094"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp075"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/651263"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.6963"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.374"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874279301206010046"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-015-0039-4"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21965"},{"key":"e_1_3_4_26_2","first-page":"1139","article-title":"Seroprevalence of herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus in children with acute lymphoblastic leukemia in Egypt","author":"Samah A. L","year":"2006","unstructured":"Samah A. L, Hanaa M. AED, Mohammed F. I, Mohamed M. H. 2006. Seroprevalence of herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus in children with acute lymphoblastic leukemia in Egypt. Saudi Med J:1139\u20131145.","journal-title":"Saudi Med J"},{"key":"e_1_3_4_27_2","unstructured":"Gorish B. 2019. Seroprevalence of cytomegalovirus infection among leukemic patients in Khartoum state 7:2\u20137."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01391-07"},{"key":"e_1_3_4_29_2","first-page":"2","article-title":"Seroprevalence of cytomegalovirus infection among leukemic patients in Khartoum State","volume":"7","author":"Dafalla ABY","year":"2018","unstructured":"Dafalla ABY, Elnil YFH, Gorish BMT. 2018. Seroprevalence of cytomegalovirus infection among leukemic patients in Khartoum State. Virol Mycol 7:2.","journal-title":"Virol Mycol"},{"key":"e_1_3_4_30_2","first-page":"28","article-title":"Seroprevalence of human cytomegalovirus (HCMV) infection in patients with haematological malignancies in Lagos, Nigeria","volume":"70","author":"Osikomaiya B","year":"2016","unstructured":"Osikomaiya B, Akinbami A, Dosunmu A, Uche E, Adediran A, Ismail A, Bonaventure B. 2016. Seroprevalence of human cytomegalovirus (HCMV) infection in patients with haematological malignancies in Lagos, Nigeria. Niger Med Pract 70:28\u201333. https:\/\/www.ajol.info\/index.php\/nmp\/article\/view\/150715.","journal-title":"Niger Med Pract"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.12816\/0046230"},{"key":"e_1_3_4_32_2","unstructured":"Catalan DT Passos SD Costa SCB Helena S Bonon A. Detection of cytomegalovirus Epstein-Barr virus and human herpes virus 6 and 7 DNA in febrile children with cancer 5:9."},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22247"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.00481-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.00481-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T14:44:40Z","timestamp":1730817880000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.00481-24"}},"subtitle":[],"editor":[{"given":"Luciana Jesus","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,5]]}},"alternative-id":["10.1128\/spectrum.00481-24"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.00481-24","relation":{},"ISSN":["2165-0497"],"issn-type":[{"type":"electronic","value":"2165-0497"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"2024-02-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00481-24"}}